Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista in Age-related Macular Degeneration
NCT01940900Phase 3Terminated
- Sponsor
- IVERIC bio
- Start
- Aug 2013
- Primary completion
- Dec 2016
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 11
01
Overview
A Phase 3 trial of pegpleranib in neovascular age-related macular degeneration (NVAMD), sponsored by IVERIC bio. Started Aug 2013; status: terminated.
02
Drugs
pegpleranib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01940900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940900.